Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy.

  title={Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy.},
  author={Carolina Gutierrez and Sergio Serrano-Villar and Nadia Madrid-Elena and Mar{\'i}a J{\'e}sus P{\'e}rez-El{\'i}as and Maria Elena Martin and Coral Barbas and Javier Ruip{\'e}rez and Eduardo Mu{\~n}oz and Ma {\'A}ngeles Mu{\~n}oz-Fern{\'a}ndez and Trevor P Castor and Santiago Moreno},
  volume={30 9},
OBJECTIVE The protein kinase C (PKC) agonist bryostatin-1 has shown significant ex-vivo potency to revert HIV-1 latency, compared with other latency reversing agents (LRA). The safety of this candidate LRA remains to be proven in treated HIV-1-infected patients. METHODS In this pilot, double-blind phase I clinical-trial (NCT 02269605), we included aviraemic HIV-1-infected patients on triple antiretroviral therapy to evaluate the effects of two different single doses of bryostatin-1 (10 or 20… CONTINUE READING
Highly Cited
This paper has 59 citations. REVIEW CITATIONS
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 22 extracted citations

59 Citations

Citations per Year
Semantic Scholar estimates that this publication has 59 citations based on the available data.

See our FAQ for additional information.

Similar Papers

Loading similar papers…